News Four Ways FDA’s New Intended Use Regulations Affect Drug and Medical Device Companies Nov 08, 2021
News Regulators Offer Fresh Guidance on Using Real-World Data to Support Regulatory Decisions Nov 08, 2021
News How Artificial Intelligence Manufacturers Can Protect Themselves Against Future Negligence Claims Nov 08, 2021
News HHS Announces Withdrawal of Good Guidance Practices and Fairness in Enforcement Rules Nov 08, 2021
News U.S. Agencies Issue Regulations on No Surprises Act’s Independent Dispute Resolution Process and Good Faith Estimate Requirements Nov 08, 2021
News CMS Proposes to Repeal Device Coverage Pathway and “Reasonable and Necessary” Regulations Nov 08, 2021
News Pharmacovigilance Considerations in the Era of Patient Centricity: Data Collected by Apps Nov 08, 2021
News Avid Bioservices Announces Expansion into Viral Vector Development and Manufacturing Services for Cell and Gene Therapy Nov 04, 2021
News EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) Nov 04, 2021
News Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma Nov 03, 2021 Posted by Sumitomo Pharma Oncology, Inc.
